Viracta Therapeutics downgraded by Leerink Partners with a new price target

8/16/24 7:39:54 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Leerink Partners downgraded Viracta Therapeutics from Outperform to Market Perform and set a new price target of $3.00 from $5.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$VIRX

Date	Price Target	Rating	Analyst
8/16/2024	$5.00 → $3.00	Outperform → Market Perform	Leerink Partners
2/1/2022	$10.00	Outperform	RBC Capital Mkts